These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38587429)

  • 1. Metabolic dysfunction-associated steatotic liver disease and risk of esophageal cancer in patients with diabetes mellitus: a nationwide cohort study.
    Jeon YJ; Han K; Lee SW; Lee JE; Park J; Cho IY; Cho JH; Shin DW
    Dis Esophagus; 2024 Jul; 37(8):. PubMed ID: 38587429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
    Jeong S; Oh YH; Ahn JC; Choi S; Park SJ; Kim HJ; Lee G; Son JS; Jang H; Lee DH; Sha M; Chen L; Kim W; Park SM
    Clin Mol Hepatol; 2024 Jul; 30(3):487-499. PubMed ID: 38711390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of fatty liver index with sudden cardiac arrest in young adults.
    Jeong JH; Kim YG; Han KD; Roh SY; Lee HS; Choi YY; Yim SY; Shim J; Kim YH; Choi JI
    Metabolism; 2024 Sep; 158():155981. PubMed ID: 39047933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
    Shikamura M; Takayama A; Takeuchi M; Kawakami K
    Diabetes Obes Metab; 2024 Aug; 26(8):3099-3109. PubMed ID: 38708591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
    Song Z; Miao X; Xie X; Tang G; Deng J; Hu M; Liu S; Leng S
    Lipids Health Dis; 2024 May; 23(1):141. PubMed ID: 38760825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.
    Sato A; Oomori Y; Nakano R; Matsuura T
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202611
    [No Abstract]   [Full Text] [Related]  

  • 7. Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes.
    Della Pepa G; Lupoli R; Masulli M; Boccia R; De Angelis R; Gianfrancesco S; Piccolo R; Rainone C; Rivellese AA; Annuzzi G; Bozzetto L
    J Endocrinol Invest; 2024 Sep; 47(9):2371-2378. PubMed ID: 38498227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    Wakabayashi SI; Tamaki N; Kimura T; Umemura T; Kurosaki M; Izumi N
    J Gastroenterol; 2024 Jun; 59(6):494-503. PubMed ID: 38570344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.
    Xiao L; Li Y; Hong C; Ma P; Zhu H; Cui H; Zou X; Wang J; Li R; He J; Liang S; Li Z; Zeng L; Liu L
    J Transl Med; 2024 Jul; 22(1):650. PubMed ID: 38997780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
    Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
    Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
    Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
    Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation Between Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Urinary Incontinence in Adult Women.
    Zhang F; Li W
    Int J Womens Health; 2024; 16():1607-1624. PubMed ID: 39372666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis.
    Amjad W; Jiang ZG; Lai M
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1038-1045. PubMed ID: 38829950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
    Kim GA; Jeong S; Jang H; Lee DH; Joo SK; Kim W
    Liver Cancer; 2024 Aug; 13(4):426-437. PubMed ID: 39114758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint effects of sleep disturbance and renal function impairment on incident new-onset severe metabolic dysfunction-associated steatotic liver disease.
    Tian T; Zeng J; Li YC; Wang J; Zhang DF; Wang DG; Pan HF; Fan JG; Ni J
    Diabetes Obes Metab; 2024 Oct; 26(10):4724-4733. PubMed ID: 39118216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between dairy-rich dietary pattern and metabolic dysfunction-associated steatotic liver disease: Findings from the Korean Genome and Epidemiology Study.
    Lee JH; Lee HS; Jeon S; Lee JH; Kwon YJ
    Dig Liver Dis; 2024 Sep; 56(9):1529-1536. PubMed ID: 38336494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between long working hours and metabolic dysfunction-associated steatotic liver disease: a nationwide population-based study in Korea.
    Baek SU; Won JU; Lee YM; Yoon JH
    Public Health; 2024 Jul; 232():188-194. PubMed ID: 38796916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study.
    Zhang Q; Xu F; Liu S; Zhu S; Zhang S; Wu J; Wu S
    Liver Int; 2024 Sep; 44(9):2315-2328. PubMed ID: 38819640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Rodriguez LA; Schmittdiel JA; Liu L; Macdonald BA; Balasubramanian S; Chai KP; Seo SI; Mukhtar N; Levin TR; Saxena V
    JAMA Netw Open; 2024 Jul; 7(7):e2421019. PubMed ID: 38990573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.